HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen

Vaccine. 2010 Nov 3;28(47):7556-62. doi: 10.1016/j.vaccine.2010.08.054. Epub 2010 Aug 25.

Abstract

There is a need for new adjuvants that will induce immune responses to subunit vaccines. We show that a short peptide, named Hp91, whose sequence corresponds to an area within the endogenous molecule high mobility group box (HMGB1) protein 1 potentiates cellular immune responses to peptide antigen and cellular and humoral immune responses to protein antigen in vivo. Hp91 promoted the in vivo production of the immunomodulatory cytokines, IFN-γ, TNF-α, IL-6, and IL-12 (p70), as well as antigen-specific activation of CD8+ T cells. These results demonstrate the ability of a short immunostimulatory peptide to serve as an adjuvant for subunit vaccines.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / pharmacology*
  • Animals
  • Antibodies / blood
  • Antigens / immunology
  • CD8-Positive T-Lymphocytes / immunology*
  • Cell Line
  • Cytokines / blood
  • Female
  • HMGB1 Protein / immunology*
  • Immunity, Cellular
  • Immunity, Humoral
  • Mice
  • Mice, Inbred C57BL
  • Ovalbumin / immunology
  • Peptides / immunology*
  • Spleen / cytology
  • Spleen / immunology

Substances

  • Adjuvants, Immunologic
  • Antibodies
  • Antigens
  • Cytokines
  • HMGB1 Protein
  • Peptides
  • Ovalbumin